Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRX Gold Ord Shs V.TRX


Primary Symbol: T.TRX Alternate Symbol(s):  TRX

TRX Gold Corporation is a Canada-based company, which is advancing the Buckreef Gold Project. The Company is engaged in the exploration, development and production of mineral property interests in the United Republic of Tanzania. The Buckreef Project's prospects include Buckreef, Bingwa, Tembo, Anfield, Eastern Porphyry and Buziba. The Buckreef Project encompasses three main mineralized zones: Buckreef South, Buckreef Main and Buckreef North. The Company produces gold at its 1,000 tons per day processing plant. Its gold development operations include the Sulphide Development Project, in which the sulphide ore encompasses over 90% of the Buckreef Main Zone's two-million-ounce gold measured and indicated mineral resources. The Buckreef Project hosts an NI 43-101 measured and indicated mineral resource of over 35.88 million tons (MT) at 1.77 grams per ton (g/t) gold containing 2,036,280 ounces of gold and an inferred mineral resource of 17.8 MT at 1.11 g/t gold for 635,540 ounces of gold.


TSX:TRX - Post by User

Comment by kuatoliveson Jan 29, 2015 6:23pm
134 Views
Post# 23379746

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:revenue

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:revenueThis is just speculation but they'll have to do an abbreviated Phase 3 (6 months?) plus say another 6-12 months for regulatory approval? Say 12-18 months from the annoucement of a licensing deal to FDA approval? Revenue for Q1 2017? Just a guess. Bilastine will be adding to the bottom line well before Bezalip. (Q1 2016).

<< Previous
Bullboard Posts
Next >>